The effects of Boswellia serrata gum resin on the blood glucose and lipid profile of diabetic patients: A double-blind randomized placebo-controlled clinical trial

How to cite

Mehrzadi, Saeed. 2015. "The effects of Boswellia serrata gum resin on the blood glucose and lipid profile of diabetic patients: A double-blind randomized placebo-controlled clinical trial." AEA RCT Registry. AEARCTR-0000898. https://doi.org/10.1257/rct.898-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Saeed Mehrzadi*

* Primary investigator

Registry ID
AEARCTR-0000898
DOI
https://doi.org/10.1257/rct.898-1.0
First registered
Last updated
Status
Completed
Trial dates
2014-03-01 – 2014-12-01
Countries
Iran (Islamic Republic of) ()
Registry record
http://www.socialscienceregistry.org/trials/898

Abstract

Aim:: Regarding traditional use of Boswellia serrata gum resin and known pharmacological effects of this gum in diabetes, we evaluated anti-hyperglycemic and lipid lowering effects of Boswellia serrata gum resin in type 2 diabetic patients in a double blind randomized placebo-control trial.
Methods and materials: Fifty six diabetic patients were randomly allocated to two groups who received the boswellia serrata gum resin or placebo capsule. The fasting blood sugar (FBS), glycosylated hemoglobin (HbA1c) as primary outcome measures and total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride and insulin level as secondary outcome measures were measured before and 8 weeks after the intervention.

Intervention

The enrolled patients were randomly assigned to receive Boswellia serrata gum capsule (n=27) as the intervention group and placebo capsule (n=29). Patients received Boswellia serrata gum 250 mg capsules or placebo capsules twice daily after meal for 8 weeks. Consumption of conventional oral hypoglycemic agents was continued in two groups simultaneously.

Experimental design

The trial is a two-arm, double-blind randomized placebo-controlled clinical trial using a parallel design with a 1:1 allocation ratio. There was no change in methods after trial commencement.

Design details

Randomization method
Fifty six eligible patients were randomized after signing the consent form in two parallel groups (Boswellia serrata gum capsule as the intervention group and placebo group) by the investigator. The randomized list was generated using Microsoft Excel with a block randomization style, as previously shown (Kim and Shin, 2014). The investigator, drug deliverers and statisticians were blind to the allocation of the patients. Moreover, due to the same shape and size of the intervention and placebo capsules, the patients were blind to the drug allocation.
Randomization unit
individual
Clusters
0
Observations
60 patients
Arms
30
Primary outcomes
The fasting blood sugar (FBS), glycosylated hemoglobin (HbA1c) as primary outcome measures and total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride and insulin level as secondary outcome measures were determined at the baseline and 8 weeks after the intervention in both groups. Blood samples were drawn after an overnight (12h) fasting and sent to hospital’s central laboratory. All the blood sample parameters were measured by using commercially available kits in hospital’s central laboratory. For final biochemical tests, when patients were blind about the results, they were asked to answer two 5-point rating scale questions ranging from 0 to 4. It was about the effectiveness and general satisfaction with treatment (0: none; 1: mild; 2: moderate; 3: potent; 4: very potent) (Matthys et al., 2003).

Cited by

No citation data available for this registration yet.

Keywords